Business Wire

KINAXIS

12.3.2024 12:01:32 CET | Business Wire | Press release

Share
Intelligent Not Artificial: The Momentum Behind AI Innovation at Kinaxis

Kinaxis (TSX:KXS), the global leader in supply chain orchestration, and a pioneer in artificial intelligence (AI) and machine learning (ML), has been laying the groundwork for continued success in the industry through a rapidly growing patent portfolio. Over the past five years, the company’s patent portfolio has grown by more than 500% and as of today, 55% of the portfolio is for AI and ML-based innovations.

The exponential growth comes as a direct result of significant investments in research and development as part of the company’s commitment to strengthen its leadership position as a trusted technology provider to chief supply chain officers globally. As part of a robust innovation program, Kinaxis continues rolling out a steady stream of AI- and ML-powered capabilities, which empower its 40,000 users to build the most intelligent supply chains on the planet.

Kinaxis uses AI innovation to drive better results while maintaining the speed and agility required to navigate modern supply chain challenges - by generating prescriptive recommendations, predicting and surfacing insights, automating processes and enhancing productivity through its platform. This human-centred approach puts people first, augmenting their capabilities to support faster and more informed decision making.

“Kinaxis has always been about making life easier for the people behind supply chains and the people they serve, and our patent portfolio is a strong indicator of our success innovating in this space,” said Chantal Bisson-Krol, vice president of AI & ML solutions at Kinaxis. “Our approach to innovating with AI/ML is no different. Our solutions are purpose-built, ensuring AI augments the people using it, so they can make decisions with more speed and accuracy. The recent AI patent growth we’ve seen demonstrates that this approach is working.”

“In an era where supply chains are increasingly complex and where agility, resilience, and sustainability are imperatives, the companies that best leverage AI/ML to enhance the capabilities of their supply chain teams will emerge as leaders,” said Tariq Farooq, former chief supply chain officer at Sanofi. “Kinaxis has a laser-like approach to pushing the boundaries of what’s possible and the growth of its AI/ML patent portfolio make it well-placed to support their client teams in their supply chain transformations.”

Pending and issued patents cover all aspects of Kinaxis technology, examples of which include:

  • Dynamic Demand Sensing patents that provide better understanding of how both internal (e.g. frequent price changes, new product introductions, changes to promotional plans) and external factors (e.g. weather, shifts in consumer behavior, local/national events) are influencing short- and long-term demand for their products.
  • Patents that significantly expedite the various tasks in a ML workflow, providing timely responses and insights for retail scale data.

Kinaxis’ AI-powered technology and patented concurrency technique allows companies to orchestrate their supply chain network end-to-end from strategic planning to last-mile delivery. Kinaxis technology helps companies supply the agricultural industry with 40% of the world’s tractors, helps keep more than 110,000,000,000 teeth clean each year, and ensures more than 35 million pets are fed nutritious meals each year.

To learn more about Kinaxis and how it is transforming the way AI is used in supply chains, please visit https://www.kinaxis.com/en/artificial-intelligence

About Kinaxis

Kinaxis is a global leader in modern supply chain management. We serve supply chains and the people who manage them in service of humanity. Our software is trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. We combine our patented concurrency technique with a human-centered approach to AI to empower businesses of all sizes to orchestrate their end-to-end supply chain network, from multi-year strategic planning through down-to-the-second execution and last-mile delivery. For more news and information, please visit kinaxis.com or follow us on LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240312570571/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye